AlloVir (NASDAQ:ALVR) Lowered to Sell at Zacks Investment Research
AlloVir (NASDAQ:ALVR – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in […]
Source: etfdailynews.com